SpectraCure reported a wider full-year net loss and declining cash reserves as it advanced clinical studies for its Q-PRO® prostate cancer system, with positive early results and new global partnerships. Additional funding will be needed by summer 2025.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.